The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US

被引：0
|
作者：
Buthainah Ghanem
Lu Shi
机构：
[1] Chapman University,Department of Pharmaceutical Economics and Policy, School of Pharmacy
[2] Oregon State University,College of Public Health and Human Sciences
来源：
BioDrugs | 2022年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：773 / 780
页数：7
相关论文
共 50 条
  • [31] Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
    Parrondo, Ricardo D.
    Sam, Keren
    Rasheed, Ahsan
    Alegria, Victoria
    Sher, Taimur
    Roy, Vivek
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [32] Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): US Myeloma CAR T Consortium Real World Experience
    Hashmi, Hamza
    Hansen, Doris K.
    Peres, Lauren C.
    Puglianini, Omar Alexis Castaneda
    Freeman, Ciara L.
    De Avila, Gabriel
    Sidana, Surbhi
    Shune, Leyla O.
    Sborov, Douglas W.
    Davis, James
    Wagner, Charlotte B.
    Kocoglu, M. Hakan
    Atrash, Shebli
    Voorhees, Peter M.
    Simmons, Gary
    Ferreri, Christopher J.
    Kalariya, Nilesh
    Sannareddy, Aishwarya
    Dima, Danai
    Khouri, Jack
    McGuirk, Joseph P.
    Locke, Frederick L.
    Baz, Rachid C.
    Patel, Krina
    Alsina, Melissa
    BLOOD, 2022, 140 : 4642 - 4645
  • [33] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
    Mancuso, Katia
    Barbato, Simona
    Talarico, Marco
    Tacchetti, Paola
    Zamagni, Elena
    Cavo, Michele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
  • [34] Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
    Costa, Luciano J.
    Hari, Parameswaran
    Berdeja, Jesus G.
    De Stefano, Valerio
    Gay, Francesca
    Hooper, Becky
    Bartlett, Meaghan
    Haltner, Anja
    Rosta, Emily
    Kumar, Shaji
    Martin, Thomas
    Mateos, Maria-Victoria
    Moreau, Philippe
    Usmani, Saad Z.
    Olyslager, Yunsi
    Schecter, Jordan M.
    Roccia, Tito
    Garrett, Ashraf
    Lee, Sam
    Nesheiwat, Tonia
    Pacaud, Lida
    Zhou, Changwei
    Samjoo, Imtiaz A.
    Lin, Yi
    Diels, Joris
    Valluri, Satish
    Weisel, Katja
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (10) : 1759 - 1767
  • [35] Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel
    Paul, Barry
    Robinson, Myra
    Symanowski, James
    Foureau, David M.
    Norek, Sarah
    Bhutani, Manisha
    Ferreri, Christopher
    Ndiaye, Ami P.
    Robinson, Jordan
    Atrash, Shebli
    Varga, Cindy
    Friend, Reed
    Pineda-Roman, Mauricio
    Smith, April
    Duda, Jessica
    Cooper, Lance
    Kitali, Amani
    Voorhees, Peter M.
    BLOOD, 2024, 144 : 7027 - 7028
  • [36] Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
    Lopez-Munoz, Nieves
    Bar, Noffar
    Diels, Joris
    van Sanden, Suzy
    Mendes, Joao
    Lee, Seina
    Hernando, Teresa
    Lendvai, Nikoletta
    Patel, Nitin
    Ishida, Tadao
    Er, Jeremy
    Harrison, Simon J.
    Shah, Urvi A.
    BLOOD, 2024, 144 : 3390 - 3391
  • [37] Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort
    Ri, Masaki
    Suzuki, Kenshi
    Ishida, Tadao
    Kuroda, Junya
    Tsukamoto, Taku
    Teshima, Takanori
    Goto, Hideki
    Jackson, Carolyn C.
    Sun, Huabin
    Pacaud, Lida
    Fujikawa, Ei
    Yeh, Tzu-Min
    Hatayama, Tomoyoshi
    Aida, Kensuke
    Sunagawa, Yoshihiro
    Iida, Shinsuke
    CANCER SCIENCE, 2022, 113 (12) : 4267 - 4276
  • [38] Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
    Dilara Akhoundova Sanoyan
    Katja Seipel
    Ulrike Bacher
    Marie-Noelle Kronig
    Naomi Porret
    Gertrud Wiedemann
    Michael Daskalakis
    Thomas Pabst
    BMC Cancer, 23
  • [39] Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
    Sanoyan, Dilara Akhoundova
    Seipel, Katja
    Bacher, Ulrike
    Kronig, Marie-Noelle
    Porret, Naomi
    Wiedemann, Gertrud
    Daskalakis, Michael
    Pabst, Thomas
    BMC CANCER, 2023, 23 (01)
  • [40] Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Berdeja, Jesus G.
    Agha, Mounzer
    Cohen, Adam D.
    Hari, Parameswaran
    Schecter, Jordan M.
    Madduri, Deepu
    Yeh, Tzu-Min
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn C.
    Allred, Alicia
    Zudaire, Enrique
    Deraedt, William
    Zhou, Changwei
    Geng, Dong
    Pacaud, Lida
    Lin, Yi
    Martin, Thomas
    Jagannath, Sundar
    BLOOD, 2021, 138
12345